Bulletin
Investor Alert

Tilray Inc. Cl 2

NAS: TLRY

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

May 12, 2021, 7:59 p.m.

/zigman2/quotes/209129655/composite

$

14.54

Change

+0.01 +0.07%

Volume

Volume 338,199

Quotes are delayed by 20 min

/zigman2/quotes/209129655/composite

Previous close

$ 15.66

$ 14.53

Change

-1.13 -7.22%

Day low

Day high

$14.48

$15.67

Open

52 week low

52 week high

$4.41

$67.00

Open

Company Description

Tilray, Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. The Company is focused on medical cannabis research, cultivation, processing and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extract...

Tilray, Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. The Company is focused on medical cannabis research, cultivation, processing and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment sales consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment sales consist of hemp seed, hemp foods, board spectrum hemp extract containing CBD which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Nanaimo, Canada.

Valuation

Price to Sales Ratio

4.95

Price to Book Ratio

3.50

Enterprise Value to Sales

5.67

Total Debt to Enterprise Value

0.29

Efficiency

Revenue/Employee

204,351.00

Income Per Employee

-263,178.00

Receivables Turnover

5.00

Total Asset Turnover

0.23

Liquidity

Current Ratio

1.91

Quick Ratio

1.40

Cash Ratio

1.05

Profitability

Gross Margin

5.45

Operating Margin

-60.49

Pretax Margin

-128.61

Net Margin

-128.79

Return on Assets

-29.43

Return on Equity

-82.25

Return on Total Capital

-17.33

Return on Invested Capital

-37.10

Capital Structure

Total Debt to Total Equity

91.28

Total Debt to Total Capital

47.72

Total Debt to Total Assets

36.08

Long-Term Debt to Equity

90.10

Long-Term Debt to Total Capital

47.10

Officers and Executives

Name Age Officer Since Title
Mr. Irwin David Simon 61 2021 Chairman & Chief Executive Officer
Mr. Carl A. Merton - 2021 Chief Financial Officer
Mr. Lloyd Brathwaite - 2021 Chief Information Officer
Dr. Joshua Eades - 2014 Chief Science Officer & Vice President
Ms. Denise Menikheim Faltischek 47 2021 Chief Strategy Officer & Head-International

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
04/30/2021 Brendan Kennedy
Director
76,000   Derivative/Non-derivative trans. at $0 per share. 0
04/30/2021 Brendan Kennedy
Director
73,954   Derivative/Non-derivative trans. at $0 per share. 0
04/30/2021 Michael B. Auerbach
Director
52,622   Derivative/Non-derivative trans. at $0 per share. 0
04/30/2021 Rebekah Dopp
Director
37,310   Derivative/Non-derivative trans. at $0 per share. 0
04/30/2021 Christine Thompson St. Clare
Director
37,310   Derivative/Non-derivative trans. at $0 per share. 0
04/30/2021 Soren W. Schroder
Director
35,817   Derivative/Non-derivative trans. at $0 per share. 0
04/17/2021 Brendan Kennedy
Director
14,568   Derivative/Non-derivative trans. at $0 per share. 0
04/17/2021 Brendan Kennedy
Director
37,020   Derivative/Non-derivative trans. at $0 per share. 0
04/01/2021 Michael B. Auerbach
Director
2,188   Derivative/Non-derivative trans. at $0 per share. 0
03/18/2021 Andrew Pucher
Chief Corporate Dev Officer
3,495   Derivative/Non-derivative trans. at $0 per share. 0
03/18/2021 Andrew Pucher
Chief Corporate Dev Officer
7,497   Derivative/Non-derivative trans. at $0 per share. 0
03/16/2021 Michael B. Auerbach
Director
31,164   0
03/16/2021 Michael B. Auerbach
Director
73,593   0
03/16/2021 Michael B. Auerbach
Director
268,095   0
03/16/2021 Michael B. Auerbach
Director
685,424   0
03/05/2021 Michael Kruteck
Chief Financial Officer
14,646   Derivative/Non-derivative trans. at $0 per share. 0
03/05/2021 Jon Levin
Chief Operating Officer
15,830   Derivative/Non-derivative trans. at $0 per share. 0
03/05/2021 Michael Kruteck
Chief Financial Officer
33,360   Award at $0 per share. 0
03/05/2021 Jon Levin
Chief Operating Officer
33,360   Award at $0 per share. 0
03/01/2021 Rebekah Dopp
Director
2,187   Derivative/Non-derivative trans. at $0 per share. 0
03/01/2021 Christine Thompson St. Clare
Director
2,187   Derivative/Non-derivative trans. at $0 per share. 0
02/23/2021 Michael B. Auerbach
Director
5,929   0
02/23/2021 Michael B. Auerbach
Director
20,392   0
02/23/2021 Michael B. Auerbach
Director
89,349   0
02/23/2021 Michael B. Auerbach
Director
228,433   0
02/19/2021 Michael Kruteck
Chief Financial Officer
23,476   Derivative/Non-derivative trans. at $0 per share. 0
02/19/2021 Jon Levin
Chief Operating Officer
26,982   Derivative/Non-derivative trans. at $0 per share. 0
02/19/2021 Michael Kruteck
Chief Financial Officer
53,191   Award at $0 per share. 0
02/19/2021 Jon Levin
Chief Operating Officer
56,738   Award at $0 per share. 0
01/25/2021 Brendan Kennedy
Director
57   0
01/25/2021 Brendan Kennedy
Director
3,371   0
01/25/2021 Michael B. Auerbach
Director
202   0
01/25/2021 Michael B. Auerbach
Director
517   0
01/25/2021 Michael B. Auerbach
Director
116   0
/news/latest/company/us/tlry

MarketWatch News on TLRY

  1. Tilray stock price target cut to $16 from $21 at Stifel Nicolaus

    9:10 a.m. May 6, 2021

    - Tomi Kilgore

  2. Tilray expects merger to create $81 mln of annual pretax cost synergies within 18 months

    6:05 a.m. May 3, 2021

    - Ciara Linnane

  3. Tilray says shares will continue to trade on Nasdaq post merger with Aphria, will trade on TSX from May 5

    6:04 a.m. May 3, 2021

    - Ciara Linnane

  4. Tilray Lowers the Bar for Merger With Aphria

    4:12 p.m. April 16, 2021

    - Max A. Cherney

  5. Loading more headlines...
/news/nonmarketwatch/company/us/tlry

Other News on TLRY

  1. Tilray’s Fundamentals Aren’t Very Solid

    2:36 p.m. May 12, 2021

    - InvestorPlace.com

  2. Harborside: Moving On From Legacy Cannabis (Podcast)

    8:00 a.m. May 12, 2021

    - Seeking Alpha

  3. Curaleaf: Still The Cannabis Leader

    5:38 p.m. May 11, 2021

    - Seeking Alpha

  4. 3 Robinhood Stocks Investors Can't Get Enough Of

    6:30 a.m. May 11, 2021

    - Motley Fool

  5. 10-Q: TILRAY, INC.

    6:11 a.m. May 10, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  6. Why Tilray Stock Dropped in April

    12:09 p.m. May 8, 2021

    - Motley Fool

  7. Here's Why Tilray Stock Is Surging

    8:48 p.m. May 7, 2021

    - Motley Fool

  8. Why OrganiGram Holdings Stock Jumped Today

    3:30 p.m. May 7, 2021

    - Motley Fool

  9. Loading more headlines...

At a Glance

Tilray, Inc.

1100 Maughan Road

Nanaimo, British Columbia V9X IJ2

Phone

1 8448457291

Industry

Farming

Sector

Agriculture

Fiscal Year-end

12/2021

Revenue

$210.48M

Net Income

$-271.07M

2020 Sales Growth

26.1%

Employees

1,030

/news/pressrelease/company/us/tlry

Press Releases on TLRY

  1. Cheapest Robinhood Stocks To Buy? 5 For Your List

    12:50 p.m. May 12, 2021

    - StockMarket.com

  2. Yesterday's Cannabis Stock Advancers and Decliners, and What to Watch For

    10:12 a.m. May 12, 2021

    - Financial News Media

  3. Best Stocks To Buy Today? 4 Cannabis Stocks In Focus

    12:49 p.m. April 20, 2021

    - StockMarket.com

  4. Loading more headlines...
Link to MarketWatch's Slice.